Imatinib Recruiting Phase 3 Trials for Non-metastatic / KIT Gene Mutation / Resected Gastrointestinal Stromal Tumors / KIT + / Gastrointestinal Stromal Tumors / High Risk of Recurrence Prevention

IndicationsStatusPurposePhase
RecruitingPrevention3
clinicaltrials.gov IdentifierTitleDrugs
NCT02260505Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)